Padcev and Dehydration - a phase IV clinical study of FDA data

Summary:

Dehydration is reported as a side effect among people who take Padcev (enfortumab vedotin-ejfv), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Keytruda, and have Transitional cell carcinoma.

The phase IV clinical study analyzes which people have Dehydration when taking Padcev. It is created by eHealthMe based on reports of 2,536 people who have side effects when taking Padcev from the FDA, and is updated regularly.

What is Padcev?

Padcev has active ingredients of enfortumab vedotin-ejfv. eHealthMe is studying from 2,538 Padcev users. Check the latest studies of Padcev.

What is Dehydration?

Dehydration (dryness resulting from the removal of water) is found to be associated with 2,751 drugs and 3,349 conditions by eHealthMe. Check the latest studies of Dehydration.

On Jul, 25, 2026

2,536 people reported to have side effects when taking Padcev.
Among them, 40 people (1.58%) have Dehydration.

Among these 40 people:

How long have people been on Padcev when they have Dehydration? *

What is the gender of people who have Dehydration when taking Padcev? *

female: 5.41 %
male: 94.59 %

What is the age of people who have Dehydration when taking Padcev? *

What are other drugs people take besides Padcev? *

Keytruda: 13 people, 32.50%
Carboplatin: 6 people, 15.00%
Gemcitabine: 4 people, 10.00%
Entecavir: 2 people, 5.00%
Gemcitabine Hydrochloride: 2 people, 5.00%
Dayvigo: 2 people, 5.00%
Cisplatin: 2 people, 5.00%
Magnesium Oxide: 2 people, 5.00%
Oxycontin: 2 people, 5.00%
Symproic: 2 people, 5.00%

What are other side effects people have besides Dehydration? *

Diarrhea: 18 people, 45.00%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 9 people, 22.50%
Rashes (redness): 8 people, 20.00%
Weight Decreased: 6 people, 15.00%
Itching: 6 people, 15.00%
Malignant Neoplasm Progression (cancer tumour came back): 5 people, 12.50%
Acute Kidney Failure: 5 people, 12.50%
Nausea And Vomiting: 5 people, 12.50%
Nausea (feeling of having an urge to vomit): 4 people, 10.00%
Constipation: 4 people, 10.00%

What are the existing conditions these people have? *

Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 22 people, 55.00%
Bladder Cancer: 4 people, 10.00%
Rashes (redness): 3 people, 7.50%
Malignant Neoplasm Of Renal Pelvis (cancer tumour of ureter): 3 people, 7.50%
Insomnia (sleeplessness): 2 people, 5.00%
Cancer Pain: 2 people, 5.00%
Constipation: 2 people, 5.00%
Metastatic Carcinoma Of The Bladder (cancer types can spread to the bladder from other place): 2 people, 5.00%
Hepatitis B: 2 people, 5.00%
Hyperglycemia (high blood sugar): 1 person, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Padcev and have Dehydration?

- Check whether Dehydration is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Padcev:

Padcev (2,538 reports)

Dehydration treatments and more:

Dehydration (173,274 reports)

Browse all side effects of Padcev:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dehydration:

Dehydration (2,751 drugs)

Browse all the conditions that are associated with Dehydration:

Dehydration (3,349 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on enfortumab vedotin-ejfv (the active ingredients of Padcev) and Padcev (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.